Chiesi Marks Key Net Zero Milestone with its First Carbon Minimal pMDI Product Submission to the MHRA for Clenil® Modulite® (beclometasone)

benefit both patients and the planet. The submission to the MHRA for use of a next generation propellant within our established beclometasone product marks the first regulatory submission for Chiesi’s carbon minimal inhaler programme anywhere in the world.” said Ralph Blom, General Manager, Chiesi UK and Ireland. “We continue to invest in our inhaler technology and our intention is to fully transition our pMDI portfolio to the new propellant by the end of 2027 in the UK. Our priority is to ensure continued clinical benefit while dramatically reducing our environmental impact.”

Pharmacokinetic studies have demonstrated therapeutic equivalence and tolerability of products formulated with HFA-152a, versus those formulated with HFA-134a, across Chiesi’s pMDI portfolio. Transitioning to the next generation propellant will reduce the carbon footprint of the company’s pMDIs by up to 90% compared to the current ones, while ensuring that patients maintain access to the device that is most effective for them.1 Following Chiesi’s transition of its pMDI portfolio to the next generation propellant, the NHS’ inhaler carbon footprint is expected to reduce by around 22% (based on current prescribing trends).2

Sarah Rust, Practice Nurse Lead, St Andrews Medical Centre, Salford, commented: “Transitioning to a lower-carbon propellant means we will be able to continue delivering effective care for people who rely on beclometasone, while taking meaningful steps to reduce the environmental impact of pMDIs. For the respiratory community, ensuring patient access to the right treatment remains a priority - and this development with the MHRA moves us forward, supporting both clinical outcomes and the NHS’ sustainability goals.”

Among inhaler types, pMDIs are the most widely used across the UK, accounting for around 70% of the 60 million inhalers prescribed each year.3,4

Today’s milestone was fuelled by Chiesi’s €400 million investment programme to reduce the carbon footprint of its pMDIs – a central part of the company’s commitment to becoming Net Zero by 2035.5 Beclometasone marks the first product to transition to the next generation propellant, with other Chiesi pMDIs to be submitted for regulatory review in the coming months.

Darshan Negandhi MRPharmS, PGCert, MAPCPharm, IPresc, Morden PCN Clinical Pharmacist and Trainer, CPPE Tutor - London, added: “Through the introduction of a more sustainable propellant into beclometasone, we’ll be able to uphold high standards of treatment without compromising on environmental responsibility. The transition of the Chiesi pMDI portfolio to the next generation propellant is a positive milestone, and will enable patients to benefit from therapeutic options that positively contribute to the NHS commitment to greener healthcare.”

About Chiesi Group

Chiesi is a research-oriented international biopharmaceutical group that develops and markets innovative therapeutic solutions in respiratory health, rare diseases, and specialty care. The company’s mission is to improve people’s quality of life and act responsibly towards both the community and the environment.

By changing its legal status to a Benefit Corporation in Italy, the US, and France, Chiesi’s commitment to create shared value for society as a whole is legally binding and central to company-wide decision-making. As a certified B Corp since 2019, we’re part of a global community of businesses that meet high standards of social and environmental impact. The company aims to reach Net-Zero greenhouse gases (GHG) emissions by 2035.

With over 85 years of experience, Chiesi is headquartered in Parma (Italy), with 31 affiliates worldwide, and counts more than 7,000 employees. The Group’s research and development centre in Parma works alongside 6 other important R&D hubs in France, the US, Canada, China, the UK, and Sweden.

For further information please visit www.chiesi.uk.com.